文献速递前列腺癌

第一代抗雄激素在转移性去势抵抗性前列腺癌中的真实世界应用:对患者结局和后续治疗的影响

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
PubMed 文献 · BJU Int · 2021-01-01

本研究基于澳大利亚多中心ePAD数据库,回顾性分析2016年1月至2019年3月纳入的634例mCRPC患者,其中322例(51%)接受第一代抗雄激素(FGA)治疗。FGA多用于低危mCRPC,其使用未显著影响后续延长生存治疗的选择或PSA50应答率;FGA治疗期间PSA50应答(37%)与总生存改善独立相关(HR 0.233,P<0.001)。

要点

  • FGA在低危mCRPC中常用,未影响后续治疗选择或疗程。
  • FGA治疗期间PSA50应答率37%,与总生存改善独立相关。
  • FGA使用与较低ISUP分级、较长至CRPC时间相关。

核心结论

  • FGA常用于较低危mCRPC,其使用未显著影响后续系统治疗的选择或疗程。
  • FGA治疗期间PSA50应答是总生存改善的独立有利预后标志。

研究设计与样本

  • 回顾性多中心队列研究,利用澳大利亚电子CRPC数据库(ePAD)识别mCRPC患者。
  • 共纳入634例mCRPC患者,其中322例(51%)接受FGA治疗,中位随访21.9个月。

主要发现

  • 接受FGA治疗的患者更可能有较低ISUP分级组(P=0.04),中位至CRPC时间更长(25.6 vs 16.0个月,P<0.001)。
  • FGA组内脏转移比例更低(5.0% vs 11.2%,P=0.005),接受 upfront 多西他赛的比例更低(P<0.001)。
  • FGA治疗期间119例(37%)患者达到PSA50应答,且与改善的总生存独立相关(HR 0.233,P<0.001)。
  • 既往FGA治疗未显著影响后续延长生存治疗的选择或其PSA50应答率。

临床怎么用

  • 在低危mCRPC患者中可考虑使用FGA,其PSA50应答可提示较好预后。
  • FGA使用不影响后续治疗决策,后续治疗选择应基于其他临床因素。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 数据来自单一国家多中心数据库,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. PATIENTS AND METHODS: The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan-Meier method and groups compared using log-rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model. RESULTS: We identified 634 patients with mCRPC, enrolled in ePAD between January 2016 and March 2019, including 322 (51%) who received FGAs. The median follow-up was 21.9 months. Patients treated with FGAs were more likely to have lower International Society of Urological Pathologists (ISUP) grade group (P = 0.04), longer median time to CRPC (25.6 vs 16.0 months, P < 0.001), and were less likely to have visceral metastases (5.0% vs 11.2%, P = 0.005) or to have received upfront docetaxel (P < 0.001). A ≥50% reduction from pre-treatment prostate-specific antigen (PSA) level (PSA50 response) during FGA treatment occurred in 119 (37%) patients and was independently associated with improved OS (hazard ratio 0.233, P < 0.001). Prior FGA treatment did not significantly influence the selection of subsequent life-prolonging treatments for mCRPC or their PSA50 response rates. CONCLUSION: In our present cohort, FGAs were commonly used in lower-risk mCRPC and their use did not significantly influence the choice or duration of subsequent systemic therapy. A PSA50 response to FGA therapy was an independent favourable prognostic marker associated with improved OS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kelly R, Anton A, Wong S, et al. Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer. BJU Int. 2021. PMID: 34622543. doi:10.1111/bju.15364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。